Use App
Trending
News
Earnings
Newsletters
Advertise
All
DIA
0.68%
SPY
0.69%
QQQ
0.27%
Trending
BROKE.X
53.55%
HOOD
10.40%
PYTH.X
5.76%
LCID
13.92%
SHI.X
1.50%
KVUE
9.56%
GYRO
18.43%
PAPL
61.64%
QURE
1.80%
CRVS
5.56%
BROKE.X
53.55%
HOOD
10.40%
PYTH.X
5.76%
LCID
13.92%
SHI.X
1.50%
KVUE
9.56%
GYRO
18.43%
PAPL
61.64%
QURE
1.80%
CRVS
5.56%
home
Symbol
TEM
TEM
Tempus AI Inc
18,334
Loading...
Loading...
Feed
News
Sentiment
Earnings
Fundamentals
Info
News
all
press releases
What's Fueling Tempus AI's Q2 Net Loss Improvement Momentum?
TEM's Q2 net loss narrows sharply, driven by surging genomics revenues, higher gross profits and tighter cost controls.
Zacks
·
1d ago
Share to Feed
More News
Hims & Hers Scales Growth Through Subscriptions and Care Expansion
HIMS fuels growth through subscriptions, expanding care offerings and building proprietary health infrastructure at scale.
Zacks
·
9d ago
Tempus' Key Acquisitions Strengthen Its AI Healthcare Leadership
TEM accelerates its healthcare edge with Paige, Deep 6 AI, and Ambry Genetics acquisitions, expanding data, tech and clinical reach.
Zacks
·
11d ago
Tempus AI or Butterfly: Which AI Health Tech Stock is a Buy Now?
BFLY trades at distressed levels with analyst targets signaling sharp upside, while TEM's premium valuation tempers its appeal.
Zacks
·
11d ago
Zacks Market Edge Highlights: ARKK, Tesla, Palantir Technologies, Robinhood Markets and Tempus
ARKK is up 27.6% in 2025, powered by bets on Tesla, Palantir, Robinhood, and Tempus-Zacks asks if it's time to buy in.
Zacks
·
12d ago
Tesla, Zoom, Nio, Tempus AI, Ubiquiti: Stocks Making The Biggest Moves Today
Tesla shares zoomed nearly 5% in Friday’s midday trade amid a broader surge in stocks following Powell’s speech.
Stocktwits
·
14d ago
Full Article
Cathie Wood's ARKK ETF is Back: Buy It or Not?
Tracey Ryniec, Zacks Senior Stock Strategist, checks in on ARK Invest's flagship ETF which is seeing big cash inflows again in 2025.
Zacks
·
15d ago
Strategic Partnerships Power Tempus AI's Healthcare Expansion
TEM deepens collaborations in oncology and neuroscience using its Lens and Next platforms to accelerate precision medicine.
Zacks
·
18d ago
Tempus AI Stock Jumps Post Q2 as EBITDA Breakeven Nears: Buy or Hold?
Tempus AI's soaring Q2 revenues, margin gains and near-EBITDA breakeven position it as a fast-rising force in precision medicine.
Zacks
·
23d ago
TEM Once Again Raises Its 2025 Sales Guidance: What's Driving the Move?
Tempus AI raises 2025 revenue outlook again after strong Q2 growth in genomics and AI-driven oncology solutions.
Zacks
·
24d ago
Latest TEM News
View
Advertisement.
Remove ads.
Advertisement.
Remove ads.
Advertisement.
Remove ads.
Advertisement.
Remove ads.
Watchlist
Trending
News
Explore
Community
Profile